II期试验-话题@MedSci

#II期试验#

98篇内容 | 1128人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947775, encodeId=cb0e194e77509, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, objectType=article, longId=738601, objectId=0e2de3860180, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2de3860180, replyNumber=0, likeNumber=33, createdTime=2022-10-10, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2de3860180, moduleTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e2de3860180)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947770, encodeId=c8d3194e77042, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, objectType=article, longId=301850, objectId=439030185039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=439030185039, replyNumber=0, likeNumber=40, createdTime=2022-07-23, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=439030185039, moduleTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=439030185039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947774, encodeId=1fdd194e77496, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, objectType=article, longId=730645, objectId=8303e3064580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8303e3064580, replyNumber=0, likeNumber=51, createdTime=2022-10-15, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8303e3064580, moduleTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8303e3064580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947773, encodeId=9530194e7734a, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, objectType=article, longId=726365, objectId=c0f8e2636523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f8e2636523, replyNumber=0, likeNumber=40, createdTime=2022-12-22, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f8e2636523, moduleTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f8e2636523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947768, encodeId=62c6194e7685f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, objectType=article, longId=218686, objectId=4c14218686ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c14218686ce, replyNumber=0, likeNumber=29, createdTime=2021-12-01, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c14218686ce, moduleTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c14218686ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947772, encodeId=e540194e772c8, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, objectType=article, longId=723982, objectId=1388e239827e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1388e239827e, replyNumber=0, likeNumber=34, createdTime=2022-09-16, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1388e239827e, moduleTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1388e239827e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947771, encodeId=93ed194e771bb, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, objectType=article, longId=724028, objectId=b171e24028fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b171e24028fa, replyNumber=0, likeNumber=34, createdTime=2022-10-21, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b171e24028fa, moduleTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b171e24028fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947764, encodeId=64ff194e7641f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验, objectType=article, longId=213616, objectId=dc3421361646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc3421361646, replyNumber=0, likeNumber=38, createdTime=2021-12-14, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3421361646, moduleTitle=J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc3421361646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947769, encodeId=783e194e769f8, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=292042, objectId=cf0429204269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0429204269, replyNumber=0, likeNumber=35, createdTime=2022-11-23, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0429204269, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0429204269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947766, encodeId=7d0f194e766c9, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Eur Urol：联合高剂量抢救性放疗和激素疗法治疗前列腺癌少发盆腔结节复发的多中心II期试验 , objectType=article, longId=214558, objectId=53bc214558eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53bc214558eb, replyNumber=0, likeNumber=40, createdTime=2022-01-22, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53bc214558eb, moduleTitle=Eur Urol：联合高剂量抢救性放疗和激素疗法治疗前列腺癌少发盆腔结节复发的多中心II期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53bc214558eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947767, encodeId=38ab194e76701, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Toll样受体激动剂治疗COVID-19，II期试验显示积极的顶线结果, objectType=article, longId=217660, objectId=dc4e21e66017, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc4e21e66017, replyNumber=0, likeNumber=49, createdTime=2022-06-08, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc4e21e66017, moduleTitle=Toll样受体激动剂治疗COVID-19，II期试验显示积极的顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc4e21e66017)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947760, encodeId=871e194e7606b, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=刺激膝关节软骨再生！FDA允许开展人类细胞外基质HST-003的I/II期试验, objectType=article, longId=208493, objectId=ac54208493a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac54208493a0, replyNumber=0, likeNumber=28, createdTime=2021-11-09, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac54208493a0, moduleTitle=刺激膝关节软骨再生！FDA允许开展人类细胞外基质HST-003的I/II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac54208493a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947758, encodeId=1caf194e758f7, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=阿尔茨海默氏病躁动症如何治疗？即将开展AXS-05的III期试验, objectType=article, longId=205150, objectId=1104205150e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1104205150e7, replyNumber=0, likeNumber=34, createdTime=2021-05-25, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1104205150e7, moduleTitle=阿尔茨海默氏病躁动症如何治疗？即将开展AXS-05的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1104205150e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947759, encodeId=a1a5194e75940, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药, objectType=article, longId=205631, objectId=e7872056314a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7872056314a, replyNumber=0, likeNumber=43, createdTime=2021-07-22, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7872056314a, moduleTitle=TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7872056314a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947756, encodeId=6082194e75609, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果, objectType=article, longId=202408, objectId=fdbb20240807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbb20240807, replyNumber=0, likeNumber=36, createdTime=2021-06-09, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbb20240807, moduleTitle=呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdbb20240807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947763, encodeId=2657194e76324, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=41, createdTime=2022-01-02, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947757, encodeId=4e17194e75771, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=AXS-07在偏头痛治疗的III期试验中取得了积极疗效, objectType=article, longId=205148, objectId=581b20514822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581b20514822, replyNumber=0, likeNumber=36, createdTime=2021-09-03, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581b20514822, moduleTitle=AXS-07在偏头痛治疗的III期试验中取得了积极疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581b20514822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947761, encodeId=39b8194e761ce, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=临床阶段生物制药公司宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验, objectType=article, longId=209970, objectId=4f092099e063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f092099e063, replyNumber=0, likeNumber=36, createdTime=2022-03-15, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f092099e063, moduleTitle=临床阶段生物制药公司宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f092099e063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947765, encodeId=09b5194e76509, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Ann Rheum Dis：托法替尼治疗强直性脊柱炎的III期试验结果, objectType=article, longId=214492, objectId=c20e21449280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c20e21449280, replyNumber=0, likeNumber=39, createdTime=2021-10-16, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c20e21449280, moduleTitle=Ann Rheum Dis：托法替尼治疗强直性脊柱炎的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c20e21449280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947762, encodeId=acd3194e7622e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, objectType=article, longId=212850, objectId=8a1421285025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1421285025, replyNumber=0, likeNumber=31, createdTime=2021-07-08, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1421285025, moduleTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1421285025)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期试验

2020-05-29

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募

2022-10-10

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析

2022-07-23

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性

2022-10-15

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果

2022-12-22

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率

2021-12-01

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验

2022-09-16

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验

2022-10-21

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验

2021-12-14

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2022-11-23

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Eur Urol：联合高剂量抢救性放疗和激素疗法治疗前列腺癌少发盆腔结节复发的多中心II期试验

2022-01-22

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Toll样受体激动剂治疗COVID-19，II期试验显示积极的顶线结果

2022-06-08

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

刺激膝关节软骨再生！FDA允许开展人类细胞外基质HST-003的I/II期试验

2021-11-09

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

阿尔茨海默氏病躁动症如何治疗？即将开展AXS-05的III期试验

2021-05-25

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药

2021-07-22

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果

2021-06-09

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2022-01-02

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

AXS-07在偏头痛治疗的III期试验中取得了积极疗效

2021-09-03

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

临床阶段生物制药公司宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验

2022-03-15

柳叶一刀 (审核中...)

前往app查看评论内容

#II期试验#

Ann Rheum Dis：托法替尼治疗强直性脊柱炎的III期试验结果

2021-10-16

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果

2021-07-08

科室
- - 订阅+
  - 更多科室
工具
服务